SK biopharmaceuticals
Daily close in US$ at the latest USD/KRW close. Source: KRX via FinanceDataReader.
SK biopharmaceuticals researches, develops, and supplies pharmaceutical drugs and active pharmaceutical ingredients, the raw chemical compounds that go into finished medicines.
Its products serve the broader healthcare and life sciences supply chain, reaching patients and medical providers. The company is listed on KOSPI, Korea's main stock exchange, and its business spans drug development, licensing of intellectual property and intangible assets, and investment in new technologies.
Summary is AI-generated and may contain errors · figures from DART filings
SK Corporation is named in the filing as the largest shareholder and has held that position since the company's founding.
SK biopharmaceuticals in five facts
What does SK biopharmaceuticals do?
SK biopharmaceuticals researches, develops, and supplies pharmaceutical drugs and active pharmaceutical ingredients, the raw chemical compounds that go into finished medicines.
Where is SK biopharmaceuticals listed and in which sector?
SK biopharmaceuticals (Korean name: SK바이오팜) trades under KRX code 326030 on KOSPI, the main board of the Korea Exchange. It is classified in the Health Care sector, Biotechnology.
How large is SK biopharmaceuticals?
Its market capitalisation was US$4.4B on 2026-10-21, which puts it in this site's large-cap group. US$ amounts are converted from won at 1 USD ≈ ₩1,325 (2026-10-21).
What were SK biopharmaceuticals's latest annual revenue and operating profit?
For fiscal year 2025, SK biopharmaceuticals reported revenue of US$533.4M, operating profit of US$153.9M and net income of US$191.1M, per its annual report on DART (data retrieved from DART on 2026-10-02). Revenue was up 29.1% on the previous year.
Where does this data come from?
Financial statements and filings come from DART, Korea's official corporate-filing system. Share prices, market capitalisation and trading status come from KRX. Company summaries are AI-generated from the filings and may contain errors; financial figures are mapped directly from DART.
Data sources and last updated
- Filings and financial statements
- DART (dart.fss.or.kr), Korea's official corporate-filing system
- Prices, market cap, trading status
- KRX (Korea Exchange), via FinanceDataReader
- Latest annual financials
- Fiscal year 2025, data retrieved from DART on 2026-10-02
- Share price and market cap
- Close of 2026-10-21
- Currency
- US$, converted from won at 1 USD ≈ ₩1,325 (2026-10-21 close)
- Company data updated
- 2026-10-21
- Company summary
- AI-generated from filings; may contain errors. Information only, not investment advice.
- Supply contract signed
SK biopharmaceuticals disclosed a supply contract with SK Life Science,Inc., worth US$46.5M, about 9% of its recent annual revenue, running through Sep 2026.
Supply contract · Sep 23 - Material management matter relevant to investment decisionsSep 17
- Change in shares held by the largest shareholderSep 15
- Report on securities held by executives/major shareholdersSep 15
- Report on securities held by executives/major shareholdersSep 15
- Supply contract signed
SK biopharmaceuticals disclosed a supply contract with SK Life Science,Inc., worth US$53.2M, about 10.1% of its recent annual revenue, running through Sep 2026.
Supply contract · Sep 14 - Investor relations (IR) meeting (notice)Sep 10
- Material management matter relevant to investment decisionsSep 10
- Change in shares held by the largest shareholderAug 31
- Report on securities held by executives/major shareholdersAug 31
- Report on securities held by executives/major shareholdersAug 31
- Supply contract signed
SK biopharmaceuticals disclosed a supply contract with SK Life Science,Inc., worth US$70.3M, about 14.1% of its recent annual revenue, running through Aug 2026.
Supply contract · Aug 18 - Operating results (consolidated) (preliminary) (fair disclosure)
SK biopharmaceuticals filed provisional (unaudited) consolidated results for Q2 2026: revenue of US$174M (+40.3% year on year), operating profit of US$68.3M (+56.9% year on year) and net income of US$59.9M (+188.1% year on year).
Earnings · Aug 5 - Supply contract signed
SK biopharmaceuticals disclosed a supply contract with SK Life Science,Inc., worth US$55.8M, about 11.5% of its recent annual revenue, running through Jul 2026.
Supply contract · Jul 28 - Supply contract signed
SK biopharmaceuticals disclosed a supply contract with SK Life Science,Inc., worth US$27.7M, about 5.9% of its recent annual revenue, running through May 2026.
Supply contract · May 27 - Operating results (consolidated) (preliminary) (fair disclosure)
SK biopharmaceuticals filed provisional (unaudited) consolidated results for Q1 2026: revenue of US$157M (+57.8% year on year), operating profit of US$61.7M (+249.7% year on year) and net income of US$70.6M (+423.5% year on year).
Earnings · May 7 - Supply contract signed
SK biopharmaceuticals disclosed a supply contract with SK Life Science,Inc., worth US$29.5M, about 8.1% of its recent annual revenue, running through Mar 2026.
Supply contract · Mar 26 - Rights offering (paid-in capital increase) decision (subsidiary)Capital raise · Mar 9
- Decision to acquire shares/equity in another company
SK biopharmaceuticals disclosed a subsidiary's acquisition of SK Life Science Labs, Inc., worth US$34.6M.
M&A · Mar 6 - Rights offering (paid-in capital increase) decision (subsidiary)Capital raise · Mar 6
- Supply contract signed
SK biopharmaceuticals disclosed a supply contract with SK Life Science,Inc., worth US$33.5M, about 8.8% of its recent annual revenue, running through Feb 2026.
Supply contract · Feb 24 - Change of 30% or more in revenue or profit/loss structure (15% for large companies)
SK biopharmaceuticals reported consolidated results for FY2025: revenue of US$481M (+29.1% year on year), operating profit of US$139M (+111.7% year on year) and net income of US$172M (+11.6% year on year).
Earnings · Feb 6 - Operating results (consolidated) (preliminary) (fair disclosure)
SK biopharmaceuticals filed provisional (unaudited) consolidated results for Q4 2025: revenue of US$132M (+19.2% year on year), operating profit of US$31.5M (+13.8% year on year) and net income of US$90.3M (−28.8% year on year).
Earnings · Feb 6 - Supply contract signedSupply contract · Jan 22